A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

971

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: Flu mRNA (Formulation B1)
BIOLOGICAL: Flu mRNA (Formulation B3)
BIOLOGICAL: Flu mRNA(Formulation A)
COMBINATION_PRODUCT: Comparator 1
COMBINATION_PRODUCT: Comparator 2
COMBINATION_PRODUCT: Comparator 3

Sponsor

GlaxoSmithKline